Floatz logo

Ansamycin

Pulmonary Non-Tuberculous Mycobacterial Infection

The University of QueenslandSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Pulmonary Non-Tuberculous Mycobacterial Infection cohort.

Asset / SponsorPhaseRating
Cefoxitin
The University of Queensland
Phase 2CCC
Tigecycline
The University of Queensland
Phase 2CCC
Ceftriaxone
The University of Queensland
Phase 2CCC
Clarithromycin
The University of Queensland
Phase 2CCC
Azithromycin
The University of Queensland
Phase 2CCC

View all 22 →

Same molecule, other indications

Ansamycin is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative · Phase 2
57 / 100
View asset →
mycobacterial infectious diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →